Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India.
作者信息
Jain Arihant, Nayak Lingaraj, Kulkarni Uday Prakash, Mehra Nikita, Yanamandra Uday, Kayal Smita, Damodar Sharat, John Joseph M, Mehta Prashant, Singh Suvir, Munot Pritesh, Selvarajan Sushil, Radhakrishnan Venkatraman, Lad Deepesh, Kapoor Rajan, Dubashi Biswajit, Bharath Ram S, Jain Hasmukh, Jayachandran P K, Lakshmanan Jeyaseelan, Mani Thenmozhi, Thorat Jayashree, Das Satyaranjan, Karunamurthy Omprakash, George Biju, Sengar Manju, Malhotra Pankaj
机构信息
Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Adult Haematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India.
出版信息
Blood Cancer J. 2022 Jan 5;12(1):2. doi: 10.1038/s41408-021-00599-w.
Abstract
摘要
相似文献
1
Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India.来自印度血液癌症登记处的血液系统恶性肿瘤患者与新冠病毒病的治疗结果。
Blood Cancer J. 2022 Jan 5;12(1):2. doi: 10.1038/s41408-021-00599-w.
2
Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time.随着时间推移，血液学患者中新冠病毒病（COVID-19）的发病率降低，预后改善。
Leukemia. 2021 Feb;35(2):632-634. doi: 10.1038/s41375-020-01015-1. Epub 2020 Aug 7.
3
Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom.英国一家大型城市医疗信托机构中血液系统恶性肿瘤合并新型冠状病毒肺炎感染住院患者的结局
Leuk Lymphoma. 2021 Feb;62(2):469-472. doi: 10.1080/10428194.2020.1838506. Epub 2020 Nov 9.
4
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub.血液系统恶性肿瘤合并 COVID-19 患者的结局：来自 ASH 研究协作数据中心的报告。
Blood Adv. 2020 Dec 8;4(23):5966-5975. doi: 10.1182/bloodadvances.2020003170.
5
ASH Registry Offers Insights on COVID-19 in Patients with Hematologic Malignancies.ASH 注册研究提供血液系统恶性肿瘤患者 COVID-19 相关信息。
Oncologist. 2021 Feb;26 Suppl 1(Suppl 1):S17-S18. doi: 10.1002/onco.13657. Epub 2020 Dec 28.
6
Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London.癌症患者感染 COVID-19 后的死亡风险：来自伦敦盖伊癌症中心和国王学院医院的分析。
Br J Cancer. 2021 Sep;125(7):939-947. doi: 10.1038/s41416-021-01500-z. Epub 2021 Aug 16.
7
Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.血液系统恶性肿瘤合并 COVID-19 患者的临床特征和转归提示，SARS-CoV-2 持续携带是一个重要问题。
Ann Hematol. 2021 Nov;100(11):2799-2803. doi: 10.1007/s00277-021-04656-z. Epub 2021 Sep 13.
8
Impact of Covid19 on a tertiary care pediatric oncology and stem cell transplant unit in Riyadh, Saudi Arabia.新型冠状病毒肺炎对沙特阿拉伯利雅得一家三级医疗儿科肿瘤与干细胞移植科室的影响。
Pediatr Blood Cancer. 2020 Sep;67(9):e28560. doi: 10.1002/pbc.28560. Epub 2020 Jul 12.
9
Increased SARS-CoV-2 reinfection frequency, attenuated severity, and risk factor analysis in patients with hematological malignancies.血液系统恶性肿瘤患者中SARS-CoV-2再感染频率增加、严重程度减轻及危险因素分析
J Infect. 2024 Sep;89(3):106233. doi: 10.1016/j.jinf.2024.106233. Epub 2024 Jul 26.
10
Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India.COVID-19 在血液恶性肿瘤患者中的临床特征和结局：来自印度三级医疗中心的经验。
Ann Hematol. 2022 Jan;101(1):69-79. doi: 10.1007/s00277-021-04644-3. Epub 2021 Sep 24.
引用本文的文献
1
Outcomes and Risk Factors in Patients with Hematologic Malignancies Following Late-Stage SARS-CoV-2 Infection.晚期严重急性呼吸综合征冠状病毒2感染后血液系统恶性肿瘤患者的结局及危险因素
J Multidiscip Healthc. 2024 Dec 8;17:5853-5865. doi: 10.2147/JMDH.S491098. eCollection 2024.
2
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.奥密克戎相关的 COVID-19 血液病患者防治措施及血液学治疗方案调整策略。
Front Cell Infect Microbiol. 2023 Oct 19;13:1207225. doi: 10.3389/fcimb.2023.1207225. eCollection 2023.
3
Impact of COVID-19 on Outcomes of Patients with Hematologic Malignancies: A Multicenter, Retrospective Study.新型冠状病毒肺炎对血液系统恶性肿瘤患者预后的影响：一项多中心回顾性研究
Mediterr J Hematol Infect Dis. 2022 Nov 1;14(1):e2022074. doi: 10.4084/MJHID.2022.074. eCollection 2022.
4
Management of Hematologic Malignancies in the Era of COVID-19 Pandemic: Pathogenetic Mechanisms, Impact of Obesity, Perspectives, and Challenges.2019冠状病毒病大流行时代血液系统恶性肿瘤的管理：发病机制、肥胖的影响、前景与挑战
Cancers (Basel). 2022 May 19;14(10):2494. doi: 10.3390/cancers14102494.
本文引用的文献
1
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).COVID-19 感染成年血液病患者：欧洲血液学协会调查（EPICOVIDEHA）。
J Hematol Oncol. 2021 Oct 14;14(1):168. doi: 10.1186/s13045-021-01177-0.
2
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.COVID-19 与干细胞移植：来自 EBMT 和 GETH 多中心前瞻性调查的结果。
Leukemia. 2021 Oct;35(10):2885-2894. doi: 10.1038/s41375-021-01302-5. Epub 2021 Jun 2.
3
Impact of COVID-19 on cancer care in India: a cohort study.新型冠状病毒肺炎对印度癌症治疗的影响：一项队列研究。
Lancet Oncol. 2021 Jul;22(7):970-976. doi: 10.1016/S1470-2045(21)00240-0. Epub 2021 May 27.
4
Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy.接受B细胞耗竭免疫疗法治疗的非霍奇金淋巴瘤患者感染新冠病毒后住院时间延长且死亡率更高。
Am J Hematol. 2021 Aug 1;96(8):934-944. doi: 10.1002/ajh.26209. Epub 2021 May 12.
5
COVID-19 and cancer registries: learning from the first peak of the SARS-CoV-2 pandemic.新冠疫情与癌症登记处：从新冠大流行的首个高峰中汲取经验教训。
Br J Cancer. 2021 May;124(11):1777-1784. doi: 10.1038/s41416-021-01324-x. Epub 2021 Mar 25.
6
Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study.淋巴瘤患者感染新型冠状病毒肺炎的危险因素及死亡率：一项多中心研究
Hemasphere. 2021 Feb 10;5(3):e538. doi: 10.1097/HS9.0000000000000538. eCollection 2021 Mar.
7
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.造血干细胞移植受者 COVID-19 的临床特征和结局：一项观察性队列研究。
Lancet Haematol. 2021 Mar;8(3):e185-e193. doi: 10.1016/S2352-3026(20)30429-4. Epub 2021 Jan 19.
8
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub.血液系统恶性肿瘤合并 COVID-19 患者的结局：来自 ASH 研究协作数据中心的报告。
Blood Adv. 2020 Dec 8;4(23):5966-5975. doi: 10.1182/bloodadvances.2020003170.
9
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.血液系统恶性肿瘤合并 COVID-19 患者的结局：对 3377 例患者的系统评价和荟萃分析。
Blood. 2020 Dec 17;136(25):2881-2892. doi: 10.1182/blood.2020008824.
10
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study.血液恶性肿瘤和癌症治疗类型对 COVID-19 严重程度和死亡率的影响：一项大型基于人群的登记研究的经验教训。
J Hematol Oncol. 2020 Oct 8;13(1):133. doi: 10.1186/s13045-020-00970-7.
Zotero 插件